Clinical data to date shows Viread as better HBV drug than Hepsera...
Will Viread work better in monotherapy than Tyzeka... that is undetermined
All indications are GILD will promote Viread if / when approved.
Viread is a Nt the approved Ns competitors - Baraclude and Tyzeka (telbivudine)
keep in mind telbivudine is the new kid on the block... as more clinical data becomes available... the picture will become clearer for telbivudine... Idenix is doing a head to head trials vs both Viread and Baraclude
Market Data 
Markets 
AI
